Show simple item record

dc.contributor.authorPorcu, P
dc.contributor.authorHudgens, S
dc.contributor.authorQuaglino, P
dc.contributor.authorCowan, Richard A
dc.contributor.authorFloden, L
dc.contributor.authorTsianakas, A
dc.contributor.authorLeoni, M
dc.contributor.authorDale, S
dc.contributor.authorDuvic, M
dc.date.accessioned2018-09-22T09:34:08Z
dc.date.available2018-09-22T09:34:08Z
dc.date.issued2018
dc.identifier.citationQuality of life in cutaneous T cell lymphoma patients treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from MAVORIC. 2018, 101 Eur J Canceren
dc.identifier.urihttp://hdl.handle.net/10541/621253
dc.titleQuality of life in cutaneous T cell lymphoma patients treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from MAVORIC.
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThomas Jefferson University, Philadelphia PAen
dc.identifier.journalEuropean Journal of Canceren


This item appears in the following Collection(s)

Show simple item record